· rebuilt nightly from public records
Signal Sheet
GT Biopharma is a listed biotechnology company in San Francisco, California. It raised $7.8M in Sep 2026 and its filings name 9 officers. Everything below links to the record it came from.
Filed to go public
CapitalSigned a material agreement
Corporate eventPick the companies and territory you sell to and get dated, sourced reasons like these for each one, ranked by who is most likely to buy now. Your list stays yours.
Want this matched to what you sell? Get early access to Pursuit Plans →The most recent events first, refreshed every night. Each links to the record it came from.
| When | What happened | Kind | Source |
|---|---|---|---|
| Oct 9, 2026 | Filed to go public | Capital | SEC filing |
| Sep 18, 2026 | Signed a material agreement | Corporate event | SEC filing |
| Sep 14, 2026 | Raised $7.8M in equity from 9 investors | Capital | SEC filing |
| Sep 14, 2026 | Signed a material agreement | Corporate event | SEC filing |
| Apr 30, 2026 | Filed to go public | Capital | SEC filing |
| Apr 3, 2026 | Signed a material agreement | Corporate event | SEC filing |
| Jan 21, 2026 | Filed to go public | Capital | SEC filing |
| May 14, 2025 | Raised $20M in equity from 2 investors | Capital | SEC filing |
The roles that matter for a seller right now. Names on this page come from SEC filings or the company's own announcements. Contacts you find with a free trial are verified before you see them. How we source names
| Role | Contact | Source | Why they matter now |
|---|---|---|---|
| Executive Officer | Michael Breen | SEC filing, Sep 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | Alan Urban | SEC filing, Sep 2026 | Named officer in the filing; part of the buying group |
| Chief Technology Officer | Charles J. Casamento | SEC filing, Sep 2026 | Technology and tooling decisions |
| Chief Technology Officer | Hilary Kramer | SEC filing, Sep 2026 | Technology and tooling decisions |
| Chief Technology Officer | David C. Mun-Gavin | SEC filing, Sep 2026 | Technology and tooling decisions |
| Chief Technology Officer | Charles Casamento | SEC filing, May 2025 | Technology and tooling decisions |
| Chief Technology Officer | Andrew Ritter | SEC filing, May 2025 | Technology and tooling decisions |
| Chief Technology Officer | Bruce Wendel | SEC filing, Feb 2025 | Technology and tooling decisions |
| Chief Technology Officer | Rajesh Shrotriya | SEC filing, Feb 2025 | Technology and tooling decisions |
Lakewave does the research, the stitching and the first draft with AI, so you spend your time selling.
Lakewave tracks raises, new leaders, hiring and filings across your accounts and territory, and tells you the day something changes.
Find the decision makers, get mailbox-verified addresses and an AI draft written for that account, which you review. Send from your own inbox with open and reply tracking and a follow-up sequence.
Which accounts to pursue, why now, who to reach and what to say, matched to your product and the buyers you sell to.
Every address Lakewave gives you is checked against GT Biopharma's mail server before you see it. Guessed addresses bounce, and bounces are what push a sender's domain toward the spam folder, so one bad list can cost a rep weeks of deliverability. Lakewave shows how each address was confirmed and leaves out the ones it cannot verify.
Use it two ways. Look up the verified address you need for a call you are already planning. Or let Lakewave do the whole job: find the accounts with a reason to buy now, the right people and their addresses, and draft a first email for each person, so you are not stitching together data sources and research by hand.
Try it on GT Biopharma with a free trial →| Headquarters | San Francisco, California, per the filing address |
| Industry group | Biotechnology |
| Ownership | Listed company |
| Raise history | $1.3M (Feb 2025) · $6M (May 2025) · $20M (May 2025) · $7.8M (Sep 2026) |
| Lakewave Rising | 37 · 2 kinds of evidence · rank in California after sign-up |
Private-sector companies in the same industry group and state, ranked by Rising score.
Yes. GT Biopharma reported a $7.8M equity raise to the SEC on Sep 14, 2026 with 9 investors.
The company's SEC filing, Sep 2026 names Michael Breen (Executive Officer) among its officers.
San Francisco, California, per the address on its SEC filing.
Select the accounts and territory you sell to and get dated reasons for every company: new budget, new leaders, new hires, with who to reach and a first draft for each contact.
Start your free trialEvery account you select comes back scored by what changed this month, with the source for each fact.
Named officers from filings and announcements, each with an address verified against the mailbox. No bounces, no guessed patterns, no scraped profiles.
Lakewave writes a first email for each person, tailored to their role and company. You edit, approve and send it from your own mailbox.
A weekly note on what changed across your targets, so no account moves without you knowing.
Free trial · No credit card · Built from public records, refreshed nightly
Compiled from public records and refreshed nightly; last updated Nov 10, 2026. Facts are as the SEC, the company's careers page or the company's own announcements published them. Check the source before acting. See something wrong? Tell us and we will correct it.